Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24333337 | 1.00 | POLB (0.47) | POLBSIRT6ALDH1A1SMN1; SMN2ACHE | |
| SCHEMBL24333332 | 0.78 | POLB (0.53) | POLBSIRT6ALDH1A1SMN1; SMN2ACHE | |
| SCHEMBL10642047 | 0.77 | GAA (0.54) | POLBSMN1; SMN2MAPK1LMNATSHR | |
| SCHEMBL10642042 | 0.77 | GAA (0.54) | POLBSMN1; SMN2MAPK1LMNATSHR | |
| SCHEMBL10641829 | 0.76 | ALDH1A1 (0.48) | POLBALDH1A1SMN1; SMN2HTR6MAPK1 | |
| SCHEMBL24333691 | 0.76 | TSHR (0.52) | ALDH1A1SMN1; SMN2MAPK1LMNATSHR | |
| SCHEMBL10641825 | 0.76 | ALDH1A1 (0.48) | POLBALDH1A1SMN1; SMN2HTR6MAPK1 | |
| SCHEMBL29469872 | 0.76 | TSHR (0.52) | ALDH1A1SMN1; SMN2MAPK1LMNATSHR | |
| SCHEMBL10641950 | 0.75 | ALDH1A1 (0.50) | POLBALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10641953 | 0.75 | ALDH1A1 (0.50) | POLBALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | POLB 566/4885SIRT6 20/4885ALDH1A1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.